Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 18, Pages -Publisher
MDPI
DOI: 10.3390/ijms22189905
Keywords
schizophrenia; cognitive deficit; antipsychotics; pharmacology; mechanisms of action
Ask authors/readers for more resources
Schizophrenia is a severe mental illness characterized by positive and negative symptoms, as well as cognitive deficits. The lack of effective treatments for cognitive impairment in schizophrenia is mainly due to its complex etiology, and recent research suggests that personalized treatments combining pharmacological and non-pharmacological measures are important for improving outcomes.
Schizophrenia is a major mental illness characterized by positive and negative symptoms, and by cognitive deficit. Although cognitive impairment is disabling for patients, it has been largely neglected in the treatment of schizophrenia. There are several reasons for this lack of treatments for cognitive deficit, but the complexity of its etiology-in which neuroanatomic, biochemical and genetic factors concur-has contributed to the lack of effective treatments. In the last few years, there have been several attempts to develop novel drugs for the treatment of cognitive impairment in schizophrenia. Despite these efforts, little progress has been made. The latest findings point to the importance of developing personalized treatments for schizophrenia which enhance neuroplasticity, and of combining pharmacological treatments with non-pharmacological measures.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available